Aware Super Pty Ltd as trustee of Aware Super Makes New Investment in Incyte Co. (NASDAQ:INCY)

Aware Super Pty Ltd as trustee of Aware Super bought a new stake in shares of Incyte Co. (NASDAQ:INCY) during the 4th quarter, Holdings Channel.com reports. The institutional investor bought 61,961 shares of the biopharmaceutical company’s stock, valued at approximately $4,280,000.

A number of other institutional investors have also recently made changes to their positions in INCY. Quintet Private Bank Europe S.A. purchased a new stake in shares of Incyte in the fourth quarter valued at $26,000. Global X Japan Co. Ltd. raised its position in Incyte by 144.7% in the 4th quarter. Global X Japan Co. Ltd. now owns 389 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 230 shares during the period. R Squared Ltd purchased a new stake in Incyte in the 4th quarter worth about $30,000. Blue Trust Inc. boosted its holdings in Incyte by 124.6% during the 4th quarter. Blue Trust Inc. now owns 593 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 329 shares during the period. Finally, Bradley & Co. Private Wealth Management LLC bought a new position in Incyte in the 4th quarter valued at $42,000. Institutional investors own 96.97% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Cantor Fitzgerald reissued a “neutral” rating on shares of Incyte in a research report on Friday, January 10th. William Blair cut shares of Incyte from an “outperform” rating to a “market perform” rating in a report on Tuesday, March 18th. JMP Securities restated a “market perform” rating on shares of Incyte in a report on Tuesday, February 11th. UBS Group assumed coverage on shares of Incyte in a research note on Tuesday, December 17th. They set a “neutral” rating and a $77.00 price objective on the stock. Finally, Citigroup reduced their price objective on shares of Incyte from $97.00 to $88.00 and set a “buy” rating for the company in a research note on Tuesday, February 11th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $74.88.

Incyte Stock Performance

NASDAQ:INCY opened at $59.22 on Tuesday. The company has a fifty day simple moving average of $65.87 and a two-hundred day simple moving average of $69.58. The company has a quick ratio of 1.94, a current ratio of 1.97 and a debt-to-equity ratio of 0.01. Incyte Co. has a 52 week low of $50.35 and a 52 week high of $83.95. The company has a market cap of $11.46 billion, a price-to-earnings ratio of 219.34, a price-to-earnings-growth ratio of 0.41 and a beta of 0.89.

Incyte (NASDAQ:INCY) last released its quarterly earnings data on Monday, February 10th. The biopharmaceutical company reported $1.09 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.48). Incyte had a return on equity of 0.05% and a net margin of 0.77%. As a group, equities analysts anticipate that Incyte Co. will post 4.86 earnings per share for the current fiscal year.

Insider Buying and Selling at Incyte

In other Incyte news, EVP Barry P. Flannelly sold 19,807 shares of the firm’s stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $67.69, for a total transaction of $1,340,735.83. Following the completion of the transaction, the executive vice president now directly owns 33,567 shares in the company, valued at approximately $2,272,150.23. This trade represents a 37.11 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Sheila A. Denton sold 599 shares of the business’s stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $69.99, for a total transaction of $41,924.01. Following the completion of the transaction, the executive vice president now directly owns 25,848 shares of the company’s stock, valued at $1,809,101.52. The trade was a 2.26 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 46,827 shares of company stock worth $3,322,618. 17.60% of the stock is currently owned by insiders.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.